New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
July 24, 2014
08:32 EDTMRKMerck initiates Phase 3 study of Letermovir
Merck announced that the first patient has been enrolled in a global Phase 3 clinical study of letermovir, an investigational antiviral agent. The multicenter, randomized, placebo-controlled study will evaluate the efficacy and safety of letermovir for the prevention of clinically-significant cytomegalovirus infection in adult CMV-seropositive recipients of allogeneic hematopoietic stem cell transplants. In the study, letermovir will be administered once daily, either as an oral tablet or IV formulation, for 14 weeks after transplant. The dose will be 240 mg once daily for participants receiving concomitant cyclosporin A and 480 mg once daily for participants not receiving cyclosporin A. The primary outcome measure of the study will be the percentage of participants with clinically-significant CMV infection through 24 weeks after transplant who were administered letermovir compared to placebo. Merck expects approximately 540 patients will be enrolled in the study at more than 70 centers in 20 countries, including the United States. The estimated study completion date is July 2017.
News For MRK From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
September 1, 2015
09:04 EDTMRKMerck reports new analyses from IMPROVE-IT study with Vytorin
Subscribe for More Information
August 30, 2015
12:33 EDTMRKDividend-rich blue chips look attractive amid market volatility, Barron's says
Subscribe for More Information
August 26, 2015
08:53 EDTMRKMerck management to meet with SunTrust
Subscribe for More Information
August 23, 2015
12:35 EDTMRKBiotech firms could see 'billions' in sales from new cancer drugs, Barron's says
Subscribe for More Information
August 21, 2015
05:44 EDTMRKStocks with implied volatility movement; DIS MRK
Subscribe for More Information
August 20, 2015
11:33 EDTMRKLeerink major pharmaceuticals analyst holds an analyst/industry conference call
Subscribe for More Information
08:38 EDTMRKMerck says to present new analyses from IMPROVE-IT study
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the theflyonthewall.com disclaimer & terms of use